Published on 8 July 2016

A type 2 diabetes treatment designed to improve blood sugar control has been approved for use in Wales.

Trulicity (dulaglutide), as a once weekly injection for people with type 2 diabetes, was recently recommended for restricted use within NHS Wales by the All Wales Medicines Strategy Group (AWMSG).

Dulaglutide has been recommended for the treatment of adults with type 2 diabetes to improve glycaemic control (blood sugar levels) in combination with other glucose-lowering treatments including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.

People with type 2 diabetes in Wales have an additional treatment option following the approval of once-weekly injection dulaglutide

More than 180,000 people in Wales currently live with type 2 diabetes, and a further 70,000 people are estimated to have undiagnosed type 2 diabetes.

An additional 540,000 people in Wales carry a high risk of developing type 2 diabetes, and this figure is rising rapidly every year.

Professor Steve Bain, Assistant Medical Director for Research and Development for Abertawe Bro Morgannwg University Health Board and Clinical Lead for the Diabetes Research Network, Wales, said: “The recommendation of Trulicity by the All Wales Medicine Strategy Group is good news as there is now an additional treatment option in Wales to help people better manage their diabetes.

“Living with diabetes is not easy and in practice we see many patients who have not yet been able to obtain optimal glycaemic control and require additional glucose-lowering medication.”

Read the All Wales Medicines Strategy Group recommendation
Support DRWF by making a donation here
Find out more about DRWF-funded research here
Find out more about DRWF fundraising here
For latest update follow DRWF on FacebookInstagram and Twitter
To receive the charity’s latest bulletins as they become available, please sign up here
Read DRWF diabetes information leaflets here
Join the Diabetes Wellness Network here

Recent News